Carlos Lopez-Gomez1, Rebecca J Levy1, Maria J Sanchez-Quintero1, Martí Juanola-Falgarona1, Emanuele Barca1,2, Beatriz Garcia-Diaz1,3, Saba Tadesse1, Caterina Garone1,4, Michio Hirano1. 1. Department of Neurology, H. Houston Merritt Neuromuscular Research Center, Columbia University Medical Center, New York, NY. 2. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 3. Unidad de Gestión Clínica de Neurociencias, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain. 4. MRC Mitochondrial Biology Unit, Cambridge University, Cambridge, United Kingdom.
Abstract
OBJECTIVE: Thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial pyrimidine salvage pathway, is essential for mitochondrial DNA (mtDNA) maintenance. Mutations in the nuclear gene, TK2, cause TK2 deficiency, which manifests predominantly in children as myopathy with mtDNA depletion. Molecular bypass therapy with the TK2 products, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life span of Tk2-deficient (Tk2-/- ) mice by 2- to 3-fold. Because we observed rapid catabolism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesized that: (1) deoxynucleosides might be the major active agents and (2) inhibition of deoxycytidine deamination might enhance dTMP+dCMP therapy. METHODS: To test these hypotheses, we assessed two therapies in Tk2-/- mice: (1) dT+dC and (2) coadministration of the deaminase inhibitor, tetrahydrouridine (THU), with dTMP+dCMP. RESULTS: We observed that dC+dT delayed disease onset, prolonged life span of Tk2-deficient mice and restored mtDNA copy number as well as respiratory chain enzyme activities and levels. In contrast, dCMP+dTMP+THU therapy decreased life span of Tk2-/- animals compared to dCMP+dTMP. INTERPRETATION: Our studies demonstrate that deoxynucleoside substrate enhancement is a novel therapy, which may ameliorate TK2 deficiency in patients. Ann Neurol 2017;81:641-652.
OBJECTIVE:Thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial pyrimidine salvage pathway, is essential for mitochondrial DNA (mtDNA) maintenance. Mutations in the nuclear gene, TK2, cause TK2 deficiency, which manifests predominantly in children as myopathy with mtDNA depletion. Molecular bypass therapy with the TK2 products, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life span of Tk2-deficient (Tk2-/- ) mice by 2- to 3-fold. Because we observed rapid catabolism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesized that: (1) deoxynucleosides might be the major active agents and (2) inhibition of deoxycytidine deamination might enhance dTMP+dCMP therapy. METHODS: To test these hypotheses, we assessed two therapies in Tk2-/- mice: (1) dT+dC and (2) coadministration of the deaminase inhibitor, tetrahydrouridine (THU), with dTMP+dCMP. RESULTS: We observed that dC+dT delayed disease onset, prolonged life span of Tk2-deficientmice and restored mtDNA copy number as well as respiratory chain enzyme activities and levels. In contrast, dCMP+dTMP+THU therapy decreased life span of Tk2-/- animals compared to dCMP+dTMP. INTERPRETATION: Our studies demonstrate that deoxynucleoside substrate enhancement is a novel therapy, which may ameliorate TK2 deficiency in patients. Ann Neurol 2017;81:641-652.
Authors: Henna Tyynismaa; Ren Sun; Sofia Ahola-Erkkilä; Henrikki Almusa; Rosanna Pöyhönen; Mari Korpela; Jari Honkaniemi; Pirjo Isohanni; Anders Paetau; Liya Wang; Anu Suomalainen Journal: Hum Mol Genet Date: 2011-09-21 Impact factor: 6.150
Authors: Caterina Garone; Beatriz Garcia-Diaz; Valentina Emmanuele; Luis C Lopez; Saba Tadesse; Hasan O Akman; Kurenai Tanji; Catarina M Quinzii; Michio Hirano Journal: EMBO Mol Med Date: 2014-08 Impact factor: 12.137
Authors: M Mancuso; L Salviati; S Sacconi; D Otaegui; P Camaño; A Marina; S Bacman; C T Moraes; J R Carlo; M Garcia; M Garcia-Alvarez; L Monzon; A B Naini; M Hirano; E Bonilla; A L Taratuto; S DiMauro; T H Vu Journal: Neurology Date: 2002-10-22 Impact factor: 9.910
Authors: Sara Laine-Menéndez; Cristina Domínguez-González; Alberto Blázquez; Aitor Delmiro; Inés García-Consuegra; Miguel Fernández-de la Torre; Aurelio Hernández-Laín; Javier Sayas; Miguel Ángel Martín; María Morán Journal: Int J Mol Sci Date: 2021-05-25 Impact factor: 5.923
Authors: Carlos Lopez-Gomez; Maria J Sanchez-Quintero; Eung Jeon Lee; Giulio Kleiner; Saba Tadesse; Jun Xie; Hasan Orhan Akman; Guangping Gao; Michio Hirano Journal: Ann Neurol Date: 2021-08-13 Impact factor: 11.274